Biologic targeting in the treatment of inflammatory bowel diseases
Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi PorroChair of Gastroenterology, “L. Sacco” University Hospital, Milan, ItalyAbstract: The etiology of inflammatory bowel disease (IBD) has not yet been clarified and immunosuppressive agents which nonspecifically reduce in...
Saved in:
Main Authors: | Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi Porro |
---|---|
Format: | article |
Language: | EN |
Published: |
Dove Medical Press
2009
|
Subjects: | |
Online Access: | https://doaj.org/article/d1dca0382bc1443b92e11b56a2f07343 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biologic targeting in the treatment of inflammatory bowel diseases [Retraction]
by: Bosani M, et al.
Published: (2014) -
Adalimumab for the treatment of Crohn’s disease
by: Andrea Cassinotti, et al.
Published: (2008) -
Therapeutic Oligonucleotides for Patients with Inflammatory Bowel Diseases
by: Marafini I, et al.
Published: (2020) -
Editorial: Game Changers in Inflammatory Bowel Diseases
by: Anita Bálint, et al.
Published: (2021) -
Biosimilars to Antitumor Necrosis Factor Agents in Inflammatory Bowel Disease
by: Al Sulais E, et al.
Published: (2020)